ISEE - Iveric bio stock rises as drug helps cut risk of potential vision loss in trials

• Iveric bio ( NASDAQ: ISEE ) said data from a post-hoc time-to-event analysis from trials suggested a reduction in rate of vision loss with avacincaptad pegol (ACP) of up to 59% compared to sham at one year.
• The GATHER1 and GATHER2 trials were evaluating ACP 2 mg versus sham treatment for the rate of geographic atrophy (GA) lesion growth in patients with GA secondary to age-related macular degeneration.
• The company noted that results were consistent in the GATHER1 and GATHER2 trials independently, signaling a 44% reduction and a 59% reduction, respectively, in the rate of vision loss with ACP 2 mg compared to sham over the first 12 months of therapy.
• In a combined analysis of the studies, patients receiving ACP 2 mg showed a 56% reduction in the rate of vision loss compared to sham over the first 1-year of treatment, according to the company.
• The company noted that the post-hoc analysis evaluates the potential vision loss signal through 12 months and is exploratory in nature.
• ISEE +5.73% to $21.97 premarket March 1

For further details see: